Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Could It be Vexas? Considering This Rare Disease Based on Hematological Findings

Lyam Carlo Chacon Rangel, Eduardo Martin-Nares, Beatriz Sánchez-Hernández, David Solar Cafaggi, Daniel Montante-Montes de Oca, Sayetzi Rico-Sánchez, Elia Ixel Apodaca Chavez, Alvaro Aguayo

Blood (2024) 144 (Supplement 1): 5646.

https://doi.org/10.1182/blood-2024-204012

Published: 2024

Journal Articles

Impact of Clonal Size and High Disease Activity on Clinical Outcomes of Paroxysmal Nocturnal Hemoglobinuria: A Multicenter Registry

Elia Ixel Apodaca Chavez, Jose Luis Alvarez Vera, Moises Xolotl Castillo, Ana Florencia Ramirez, Juan Manuel Perez, Jose Antonio Dela Peña Celaya, Laura Ceja Ramirez, David Solar Cafaggi, Junice Teresita Sosa Romero, Alvaro Aguayo, Efreen Montano Figueroa

Blood (2024) 144 (Supplement 1): 5683.

https://doi.org/10.1182/blood-2024-203775

Published: 2024

Journal Articles

Bridging the Gap: Evaluating Discrepancies in Disease Knowledge and Expectations between Patients and Physicians in Hematologic Malignancies

Santiago Riviello-Goya, Analy Mora, Daniela Vieyra Santiago, Akari Erandi Chávez Coronel, Fausto Alfredo Rios Olais, Gladys Patricia Agreda-Vásquez, Elena Juventina Tuna Aguilar, Elia Ixel Apodaca Chavez, Alvaro Aguayo, Roberta Demichelis

Blood (2023) 142 (Supplement 1): 5090.

https://doi.org/10.1182/blood-2023-185342

Published: 2023

Journal Articles

Castleman's Disease:Clinicopathological Characteristics of a Cohort of Hispanic Patients

Alfonso Orozco, Daniel Montante-Montes, María José Lizardo-Thiebaud, Sergio Rodriguez-Rodriguez, Cinthya Monroy-Ramos, Berta Riveros Gilardi, Alec Seidman-Sorsby, Isabel García Carrera, José De Jesús Sandoval López, Alvaro Aguayo, Déborah Martínez-Baños

Blood (2022) 140 (Supplement 1): 12516–12517.

https://doi.org/10.1182/blood-2022-168268

Published: 2022

Journal Articles

Infectious Complications and Their Relationship with Mortality in Patients Newly Diagnosed with Multiple Myeloma

Juan Luis Luis Ontiveros, Sandra Rajme-López, Alfonso Orozco, Sergio Rodriguez-Rodriguez, Santiago Riviello-Goya, Alec Seidman-Sorsby, Alvaro Aguayo, Déborah Martínez-Baños

Blood (2022) 140 (Supplement 1): 12508–12509.

https://doi.org/10.1182/blood-2022-167882

Published: 2022

Journal Articles

Prognosis in Patients with Human Immunodeficiency Virus Infection and Advanced Clinical Stage Classic Hodgkin's Lymphoma

Juan J delMoral-Diez, MD, Elena Juventina Tuna-Aguilar, MD, Alvaro Aguayo, MD, Antonio Olivas-Martinez, MD, Gladys P Agreda-Vasquez, MD

Blood (2019) 134 (Supplement_1): 5281.

https://doi.org/10.1182/blood-2019-123792

Published: 2019

Journal Articles

Cost-Effectiveness of the Regimen Proposed By the International Consortium on Acute Promyelocytic Leukemia in the Treatment of Newly Diagnosed Patients with Acute Promyelocytic Leukemia

Sergio Rodriguez-Rodriguez, MD, Roberta Demichelis-Gómez, MD, Maria Jose Diaz-Huizar, MD, Lorena Guerrero-Torres, MD, Alan Pomerantz, MD, Maria del Pilar Ortiz-Vilchis, PhD, Alvaro Aguayo, MD

Blood (2017) 130 (Supplement 1): 5601.

https://doi.org/10.1182/blood.V130.Suppl_1.5601.5601

Published: 2017

Journal Articles

Prognostic Factors and Outcomes in Adults with Hemophagocytic Lymphohistiocytosis: A Single-Center Experience

Elia Ixel Apodaca, Resident, Alvaro Aguayo, MD, Roberta Demichelis, MD, Sergio Rodriguez, Resident, Elena Juventina Tuna, MD, Alan Pomerantz, MD

Blood (2017) 130 (Supplement 1): 4823.

https://doi.org/10.1182/blood.V130.Suppl_1.4823.4823

Published: 2017

Journal Articles

Clinical Characteristics and Outcomes of Hemophagocytic Lymphohistiocytosis-Associated Lymphoma: A Case-Control Study

Elia Ixel Apodaca, Resident, Roberta Demichelis, MD, Alvaro Aguayo, MD, Sergio Rodriguez, Resident, Elena Juventina Tuna, MD, Alan Pomerantz, MD

Blood (2017) 130 (Supplement 1): 5205.

https://doi.org/10.1182/blood.V130.Suppl_1.5205.5205

Published: 2017

Journal Articles

Hyperviscosity Syndrome: A 30-Year Experience in a Tertiary Referral Center in Mexico City

FM Armillas-Canseco, MD, CF Hernández-Mata, MD, IA Gómez-Ruiz, MD, Alvaro Aguayo, MD, D Martínez-Baños, MD

Blood (2015) 126 (23): 4741.

https://doi.org/10.1182/blood.V126.23.4741.4741

Published: 2015

Journal Articles

Multiple Myeloma: Experience in a Tertiary Referral Center in Mexico City

Christianne Bourlon, MD, C Vargas-Serafín, MD, Alvaro Aguayo, MD, D Martínez-Baños, MD

Blood (2015) 126 (23): 5327.

https://doi.org/10.1182/blood.V126.23.5327.5327

Published: 2015

Journal Articles

Treatment of Adult Patients with the Modified Protocol of the International Consortium on Acute Promyelocitic Leukemia (IC-APL)

Alvaro Aguayo, Jorge Contreras Cisneros, Adriana Lopez Rosas, Juan Mauricio Vera Zertuche, Erick Crespo Solís

Blood (2014) 124 (21): 5341.

https://doi.org/10.1182/blood.V124.21.5341.5341

Published: 2014

Journal Articles

The Age of Mexican Patients with Chronic Myeloid Leukemia (CML) Ph+ Is Quite Younger Than the Reported in USA and European Series.

Pablo Vargas-Viveros, M.D., Rafael Hurtado Monroy, MD, Eduardo Cervera, MD, Carlos Best, M.D., Alvaro Aguayo, M.D., Myrna Candelaria, MD

Blood (2009) 114 (22): 4291.

https://doi.org/10.1182/blood.V114.22.4291.4291

Published: 2009

Journal Articles

Nilotinib (AMN107) Can Induce Complete Cytogenetic Responses (CCyR) and Molecular Responses in Patients (Pts) with Advanced Chronic Myeloid Leukemia (CML) Resistant or Intolerant to Imatinib Mesylate (IM). Report of the Compassionate Use Program of Nilotinib in Mexico

Blood (2008) 112 (11): 4275.

https://doi.org/10.1182/blood.V112.11.4275.4275

Published: 2008

Journal Articles

Compassionate Use of Nilotinib (AMN107) in Mexican Patients with Chronic Myeloid Leukemia (CML) Resistant or Intolerant to Imatinib.

Manuel Ayala, MD, Rafael Hurtado, MD, Kevin Nacho, MD, Norma Tapia, MD, Martha Alvarado, MD, Alvaro Aguayo, MD, Sergio Cleto, MD, Yolanda Lugo, MD, Gustavo Reyes, MD, Pablo Vargas, MD, Angel Herrera, Luis Antonio Meillon, MD

Blood (2007) 110 (11): 4578.

https://doi.org/10.1182/blood.V110.11.4578.4578

Published: 2007

Journal Articles

Chronic Myeloid Leukemia. 15-Years Experience at a Single Institution in Mexico City.

Alvaro Aguayo, MD, Eunice Garcia-Alvarez, M.D., Yael Cazares-Ordonez, M.D., Erick Crespo-Solis, M.D., Deborah Martinez-Banos, M.D., Guadarrama-Beltran S.W. Elizabeth, Eduardo E. Cervera-Ceballos, M.D., Xavier Lopez-Karpovitch, M.D.

Blood (2007) 110 (11): 4557.

https://doi.org/10.1182/blood.V110.11.4557.4557

Published: 2007

Journal Articles

A Pilot Study of Treatment with Mesterlone, Prednisone and Low-Dose Thalidomide for Patients with Myelodysplastic Syndromes.

Alvaro Aguayo, MD, Eunice Garcia-Alvarez, M.D., Erick Crespo-Solis, M.D., Deborah Martinez-Banos, M.D., Xavier Lopez-Karpovitch, M.D.

Blood (2007) 110 (11): 4598.

https://doi.org/10.1182/blood.V110.11.4598.4598

Published: 2007

Journal Articles

Longitudinal Assessment of Nutritional Status in Adults with Acute Leukemia.

Aurora Serralde, MD, Erick Crespo-Solis, MD, Xavier Lopez-Karpovitch, MD, Ericka Damasco, RD, Adriana Rosas-Lopez, LE, Alvaro Aguayo, MD

Blood (2007) 110 (11): 4360.

https://doi.org/10.1182/blood.V110.11.4360.4360

Published: 2007

Journal Articles

Imatinib Alone (IA) Vs. Imatinib + Ara-C (IMAC): A Randomized Phase III Clinical Trial for the Treatment of Early Phase (EP) Chronic Myeloid Leukemia (CML) Ph+. Preliminary Report of Mexican Cooperative Leukemia Group (GRUMELA).

Rafael Hurtado Monroy, MD, Pablo Vargas-Viveros, MD, Eduardo Cervera, MD, Myrna Candelaria, MD, Alvaro Aguayo, MD, Emma Gallardo, MD, Eucario Leon, MD, Juan Labardini, MD, Ricardo Sosa, MD, Rogelio Paredes, MD, Fernando Romero, MD, Oscar Perez, MD, Omar Coronel-Ayala, MD

Blood (2004) 104 (11): 1015.

https://doi.org/10.1182/blood.V104.11.1015.1015

Published: 2004

Journal Articles

Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes

Alvaro Aguayo, Hagop Kantarjian, Taghi Manshouri, Cristi Gidel, Elihu Estey, Deborah Thomas, Charles Koller, Zeev Estrov, Susan O'Brien, Michael Keating, Emil Freireich, Maher Albitar

Blood (2000) 96 (6): 2240–2245.

https://doi.org/10.1182/blood.V96.6.2240

Published: 2000

NARROW

Could It be Vexas? Considering This Rare Disease Based on Hematological Findings

Impact of Clonal Size and High Disease Activity on Clinical Outcomes of Paroxysmal Nocturnal Hemoglobinuria: A Multicenter Registry

Bridging the Gap: Evaluating Discrepancies in Disease Knowledge and Expectations between Patients and Physicians in Hematologic Malignancies

Castleman's Disease:Clinicopathological Characteristics of a Cohort of Hispanic Patients

Infectious Complications and Their Relationship with Mortality in Patients Newly Diagnosed with Multiple Myeloma

Prognosis in Patients with Human Immunodeficiency Virus Infection and Advanced Clinical Stage Classic Hodgkin's Lymphoma

Cost-Effectiveness of the Regimen Proposed By the International Consortium on Acute Promyelocytic Leukemia in the Treatment of Newly Diagnosed Patients with Acute Promyelocytic Leukemia

Prognostic Factors and Outcomes in Adults with Hemophagocytic Lymphohistiocytosis: A Single-Center Experience

Clinical Characteristics and Outcomes of Hemophagocytic Lymphohistiocytosis-Associated Lymphoma: A Case-Control Study

Hyperviscosity Syndrome: A 30-Year Experience in a Tertiary Referral Center in Mexico City

Multiple Myeloma: Experience in a Tertiary Referral Center in Mexico City

Treatment of Adult Patients with the Modified Protocol of the International Consortium on Acute Promyelocitic Leukemia (IC-APL)

The Age of Mexican Patients with Chronic Myeloid Leukemia (CML) Ph+ Is Quite Younger Than the Reported in USA and European Series.

Nilotinib (AMN107) Can Induce Complete Cytogenetic Responses (CCyR) and Molecular Responses in Patients (Pts) with Advanced Chronic Myeloid Leukemia (CML) Resistant or Intolerant to Imatinib Mesylate (IM). Report of the Compassionate Use Program of Nilotinib in Mexico

Compassionate Use of Nilotinib (AMN107) in Mexican Patients with Chronic Myeloid Leukemia (CML) Resistant or Intolerant to Imatinib.

Chronic Myeloid Leukemia. 15-Years Experience at a Single Institution in Mexico City.

A Pilot Study of Treatment with Mesterlone, Prednisone and Low-Dose Thalidomide for Patients with Myelodysplastic Syndromes.

Longitudinal Assessment of Nutritional Status in Adults with Acute Leukemia.

Imatinib Alone (IA) Vs. Imatinib + Ara-C (IMAC): A Randomized Phase III Clinical Trial for the Treatment of Early Phase (EP) Chronic Myeloid Leukemia (CML) Ph+. Preliminary Report of Mexican Cooperative Leukemia Group (GRUMELA).

Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only